API | phenylpropanolamine

phenylpropanolamine (Propadrine) Report issue

Small molecule Withdrawn

AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem repoDB

Active Ingredient History

NOW

(+)-Phenylpropanolamine is an enantiomer of propanolamine. The substance has low adrenergic activity and exerts measurable physiological effect only at high doses, which were lethal to experimental animals tested. Phenylpropanolamine belongs to the sympathomimetic amine class of drugs and is structurally related to ephedrine. The effects of phenylpropanolamine are largely the result of alpha-adrenergic agonist activity resulting from both direct stimulation of adrenergic receptors and release of neuronal norepinephrine. Phenylpropanolamine containing products has been withdrawn by FDA due to the association of phenylpropanolamine use with increased risk of hemorrhagic stroke. ^NCATS

Chemistry

SMILES: OS(O)(=O)=O.C[C@H](N)[C@H](O)C1=CC=CC=C1.C[C@H](N)[C@H](O)C2=CC=CC=C2
InChIKey: QSGAFDSLNHRMIQ-SMBKYJPPSA-N
Mol. Mass: 400.49
ALogP: 1.07 Partition coefficient
ChEMBL Molecules:

phenylpropanolamine hydrochloride

phenylpropanolamine polistirex

phenylpropanolamine

More Chemistry

Pharmacology

Mechanisms of Action:
- Sodium-dependent noradrenaline transporter (Homo sapiens) ^UniProt
- Alpha-1A adrenergic receptor (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Oral
Pro Drug: No

Combination drugs

codamine ( hydrocodone (hycodan), phenylpropanolamine (Propadrine) )

cold capsule v ( dexchlorpheniramine maleate (polaramine), phenylpropanolamine (Propadrine) - other name: cold capsule iv )

corsym ( chlorpheniramine (ChlorTrimeton), phenylpropanolamine (Propadrine) )

Organizations (8)

Research & Development (4)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (4)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (9)

Approved Indications (1)

Hypotension (approved 1936)

Experimental Indications - Clinical Trial Phases 1-4 (8)

Arterial Occlusive Diseases (Phase 1)

Ischemic Stroke (Phase 4)

Nasal Obstruction ()

Obesity ()

Otitis ()

Peripheral Arterial Disease (Phase 3)

Sinusitis ()

Vestibular Neuronitis (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 5
# of Trial Organizations: 4

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue